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Structured summary  1 
Background: National responses to healthcare-associated infections vary between high-income 2 
countries but when analysed for contextual comparability, interventions can be assessed for 3 
transferability.  4 
Aim: To identify learning from country-level approaches to addressing meticillin-resistant 5 
Staphylococcus aureus (MRSA) in Japan and England. 6 
Methods: A longitudinal analysis (2000-17), comparing epidemiological trends and policy 7 
interventions. Data from 441 textual sources concerning infection prevention and control (IPC), 8 
surveillance, and antimicrobial stewardship interventions were systematically coded for: type - 9 
mandatory requirements, recommendations, or national campaigns; method - restrictive, persuasive, 10 
structural in nature; level of implementation - macro (national), meso (organisational), micro 11 
(individual) levels. Healthcare organisational structures and role of media were also assessed.  12 
Findings: In England significant reduction has been achieved in number of reported MRSA 13 
bloodstream infections. In Japan, in spite of reductions, MRSA remains a predominant infection. 14 
Both countries face new threats in the emergence of drug-resistant Escherichia coli. England has 15 
focused on national mandatory and structural interventions, supported by a combination of 16 
outcomes-based incentives and punitive mechanisms, and multidisciplinary IPC hospital teams. 17 
Japan has focused on (non-mandatory) recommendations and primarily persuasive interventions, 18 
supported by process-based incentives, with voluntary surveillance. Areas for development in Japan 19 
include resourcing of dedicated data management support and implementation of national 20 
campaigns for healthcare professionals and the public.    21 
Conclusion: Policy interventions need to be relevant to local epidemiological trends, while  22 
acceptable within health system cultures and public expectations. Cross-national learning can help 23 
inform the right mix of interventions to create sustainable and resilient systems for future infection 24 
and economic challenges. 25 
 26 
Keywords  27 
Meticillin-resistant Staphylococcus aureus; antimicrobial resistance; infection prevention and control; 28 
healthcare-associated infections  29 
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Introduction 30 
Antimicrobial resistance (AMR) and healthcare-associated infections (HCAIs) remain a critical global 31 
challenge[1]. While a standard template for National Action Plans for AMR has been suggested, 32 
countries have adopted different interventions to address AMR and HCAIs. A better understanding of 33 
what has been attempted at the national level can offer improved contextualisation for the often 34 
challenging implementation of large-scale interventions such as National Action Plans. By comparing 35 
international responses across different countries, a look at the wider policy setting can help  36 
transfer of learning. Global transfer of learning has influenced UK initiatives in the past (e.g. primary 37 
care organisational development [2]) but for infection prevention and control (IPC), England has 38 
deviated from its European neighbours in policy approach and particularly the amount of 39 
information available in the public domain [3]. International collaboration and cross-border learning 40 
from innovative models tackling AMR are encouraged by the UK Department of Health (DH)[4] and 41 
Japan Ministry of Health Labour and Welfare (MHLW)[5]. High-income countries, such as Japan and 42 
UK, face a further challenge arising from ageing populations, which require careful consideration of 43 
sustainable approaches.   44 
The AMR National Action Plans in both countries cover similar overarching themes. The Japanese 45 
government formulated its plan in April 2016, aiming to cut total antibiotic usage by 33% of the 46 
current level by 2020 [5]. However, the UK, in its Five Year AMR Strategy (2013-2018), has 47 
approached the setting of AMR targets differently [4]. The UK is implementing continuous yearly 48 
review and revised  targets using baselines, starting with ten different drug-bug combinations [4]. 49 
MRSA is not included because of the earlier focus and achievement [6], [7]. Japan has implemented a 50 
reduction programme with a set target for achievement by 2020 for each one of six different drug-51 
resistant bacteria, including MRSA [5].  52 
This study addressed the question: What can be learnt from approaches for addressing MRSA 53 
between two high-income countries? 54 
 55 
Methods 56 
This study involved the collection and analysis of secondary data to systematically map and 57 
understand the trajectory of national-level interventions to address MRSA as follows.  58 
(i) Observing the epidemiological setting 59 
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The most complete datasets (chronologically) in each country were accessed,  data extracted  and 60 
trends plotted (on MS Excel). For England, the publicly accessible Public Health England (formerly 61 
Health Protection Agency) data were used [8]–[12]. We included four infections for which NHS acute 62 
hospital trusts have been subject to mandatory surveillance and public reporting in England: 63 
methicillin-resistant Staphylococcus aureus (MRSA), meticillin-sensitive S. aureus (MSSA), and E. coli 64 
bloodstream infections (BSIs), and Clostridium difficile infection. The financial year 2001/2 was the 65 
start point of the analysis in line with initiation of mandatory surveillance, and public reporting of 66 
MRSA. Other Gram-negative organisms, Psedomonas aeruginosa and Klebsiella species, which 67 
became subject to mandatory surveillance and public reporting only in 2017, were not included in 68 
this study. 69 
In Japan, since 1999 MRSA infections have been the subject of sentinel surveillance with 500 70 
designated hospitals required to report their monthly number of patients with MRSA infection [13]. 71 
This covers approximately 6% of 8000 hospitals in Japan. In 2000, The Japan Nosocomial Infections 72 
Surveillance (JANIS), organised by the MHLW, was launched to collect data on multidrug-resistant 73 
organism (MDRO) nosocomial infections such as MRSA on a voluntary basis.  JANIS member hospitals 74 
are required to submit surveillance data monthly. The JANIS system provides anonymous ‘Open 75 
Reports’ for the public (quarterly & annually) and ‘Feedback Reports’ for member hospitals (monthly 76 
& annually). Data from the divisions of Antimicrobial-Resistant Bacterial Infection (ARBI) and Clinical 77 
Laboratory (CL) at JANIS were accessed [14]. These data represent 10% and 19.5% of hospitals (2016) 78 
respectively [15].  The CL division reports prevalence of  bacteria amongst clinical isolates based on 79 
microbiological data [14]. Whilst ARBI data have less coverage, they are used here as capture the 80 
incidence of seven different (multi)drug-resistant infections associated with six bacteria, including 81 
MRSA, amongst hospitalised patients. The ARBI data are more comparable with England data on 82 
MRSA BSI rather than the CL data. The CL data are included as supplementary data (Appendix A, 83 
Figure A.1) as include additional pathogens. Pre-2007 data for Japan were excluded, as longitudinal 84 
comparison is inappropriate due to different data collection systems. Across the countries, there is a 85 
difference in the denominators for epidemiological data due to different data collection methods.  86 
 87 
(ii) Assessment of the health policy setting 88 
To map policy interventions for the period 2000-17, we purposefully sampled secondary data 89 
sources, concerning wider IPC, surveillance, antimicrobial stewardship as key areas to address AMR, 90 
including MRSA [16].  The start point of 2000 is used for both countries to align with publication of 91 
two key reports by the US Institute of Medicine [17], [18] pointing out prevalence of hospital 92 
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infections, harnessing national commitment to patient safety, followed by country actions globally. 93 
As a first study to provide a rapid, efficient, but in-depth comparison of approaches post-2000, 94 
between Japan and England, a decision to use secondary sources was taken; setting the ground for 95 
future interviews and surveys. 96 
The sampling was informed by field experts, such as senior clinicians and policy makers in each 97 
country. For Japan, a total of 275 textual sources were analysed from four main categories: (a) policy 98 
documents, guidelines, and legislation produced by Japan’s health bodies; (b) hospital human 99 
resource documents, board minutes, reports and strategies on IPC (for a sample of five hospitals in 100 
Japan); (c) documentary evidence from professional associations; (d) documentary material from 101 
outside healthcare, such as newspaper articles concerning HCAIs and AMR.  For England, we 102 
supplemented archival data of previous research conducted by the research team [6], [19], which 103 
resulted in 322 textual sources being retrieved and analysed for (a)-(c). We did not conduct analysis 104 
for media materials for England in this study, as this has been captured elsewhere in recent years 105 
[20], [21] with a frequency of reporting ‘AMR’/’antibiotic resistance’ and ‘superbug’ in the media 106 
averaging at up to 4.7 per month in popular and broadsheet newspapers between 2010-15 [22]. 107 
 108 
Using keyword searches taking into account relevant key literature [7], [23]–[26], an inventory of 109 
interventions was compiled. This inventory was then refined through an iterative process, including a 110 
series of team virtual discussions and emails about its appropriateness. Data from 441 textual 111 
sources were then independently and systematically mapped and coded along three dimensions: a. 112 
type - mandatory requirements, recommendations, or national campaigns; b. method – restrictive, 113 
persuasive, and/or structural in nature [27], [28]; c. level of implementation - macro (national), meso 114 
(organisational), and/or micro (individual) levels. This was done independently and concurrently 115 
between the research teams. A further 156 materials were also analysed for role of media (for Japan) 116 
and healthcare organisational structures.  117 
Examples for restrictive interventions include limits or required approvals, such as formulary 118 
restriction requiring prior authorisation of prescriptions by infectious diseases physicians. Persuasive 119 
interventions refer to education, training, local consensus processes, advice, audit and feedback. 120 
Structural interventions include shifting towards electronic records, provision of rapid laboratory 121 
testing and technology, and organisation of quality monitoring mechanisms. Two researchers 122 
independently coded all data for each country (SM - Japan, MI- England). A second, independent 123 
coding was carried out for Japan for 30% of the interventions (MI bilingual). A second, independent 124 
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coding was carried out for England for 30% of the interventions (RA & YK). A third level of 125 
independent coding was carried out for discrepancies arising (RA). Disagreements in the results were 126 
resolved through team (virtual) discussions (SM, SK, MI, RA). 127 
 128 
(iii) Wider contextual analysis 129 
For a broader contextualisation of policy interventions we gathered information based on a classic 130 
policy appraisal framework , namely Leichter’s:  (i) situational factors (i.e. change of government and 131 
national leadership, health, healthcare utilisation); (ii) structural factors (i.e. socio-economic 132 
indicators, health expenditures, health workforce, population); (iii) cultural factors (i.e. cultural 133 
values); and (iv) exogenous factors (i.e. influence of international institutions) [29]. 134 
The approaches above allowed a multi-dimensional comparison of approaches over time between 135 
Japan and England.    136 
 137 
Results 138 
(i) The Epidemiological Setting  139 
MRSA remains highly prevalent in Japanese hospitals. Although MRSA infections have been 140 
decreasing over the last decade, the speed of decline appears to have slowed down after 2013, with 141 
2016 rates at 311 per 100 000 hospitalized patients [15].  The trend of other (multi)drug-resistant 142 
bacterial infections based on ARBI data either showed a decline or did not change during the 143 
observed period (2007-2016) (Figure 1). CL data show E. coli and drug-resistant E. coli 144 
(cephalosporin, fluoroquinolone) isolates have rapidly increased in recent years, reaching similar 145 
levels to S. aureus isolates (Appendix A, Figure A.1). 146 
In England, there was a sharp drop in the rates of MRSA BSIs between 2006/7 and 2009/10, and then 147 
the speed of decline slowed down between 2009/10 and 2011/12. MRSA levels have plateaued since 148 
2011/12 with all reported cases per 100 000 bed days below 5.  Not all trends are in the right 149 
direction despite being subject to mandatory surveillance since 2001 (later implementation for E. 150 
coli, MSSA – 2011/12) (Figure 2). E. coli represents a rapid increase and the most frequent cause of 151 
BSIs; 41% of these were resistant to co-amoxiclav (commonest antibiotic used in hospitals) in 2016 152 
[30]. 153 
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Regional variation is also reported between Europe and Asia as well as England and Japan. S. aureus’s 154 
resistance to methicillin was reported as 6.7% (invasive isolates, 2016) in the UK, 13.7% in EU/EEA 155 
[31], whereas Japan and Asian Network for Surveillance of Resistant Pathogens accounted for 53% 156 
(comprehensive, 2012) and 64% (blood isolates, 2012) respectively [32].  157 
(ii) The Health Policy Setting 158 
Since 1996, the Japanese government has promoted infection control in hospitals using a medical 159 
reimbursement system. Hospitals which have in place methods for developing staff and capacity 160 
building as well as taking part in surveillance, establishment of a hospital infection control 161 
department/committee, and associated activities, are eligible to apply for an additional fee through 162 
reimbursement systems. Those hospitals that do not have systems to monitor optimal use of 163 
antimicrobials are barred from applying for this fee. A key feature of monitoring must be either a 164 
notification or permission system for broad spectrum antibiotics.[33] 165 
In England, IPC policy towards MRSA has evolved dramatically since 2001. It transformed from the 166 
under-resourced ‘Cinderella model’ [34], [35], and HCAIs being seen as unavoidable, to a vertical and 167 
largely top-down performance management model. Mandatory surveillance and public reporting of 168 
MRSA BSI cases in hospitals in 2001 was closely followed by national and local stretch targets, and 169 
then embedded as ‘objectives’ in NHS operating/outcomes frameworks. More recently, the 170 
approach has evolved to a ‘zero tolerance’ model strategically applied to avoidable HCAIs with IPC 171 
indicator basket (e.g. quality requirement, threshold, measurement methods, breach)[36]; and more 172 
specifically for MRSA with post infection reviews being required to investigate how an incidence 173 
occurred, and identify lessons and actions to prevent such instance from reoccurring in the future 174 
[37]. 175 
Political pressure generated through a series of critical independent reports (e.g. National Audit 176 
Office reports [35], Robert Francis Inquiry Reports into Mid-Staffordshire NHS Foundation Trust [38]), 177 
and public outcry through increased media stories about dirty wards and hospital superbugs all acted 178 
as drivers to this policy trajectory. Nurses and medical consultants within infection prevention teams 179 
are required to have specialist training in infection prevention and cleanliness, set out within the 180 
2015 Code of Practice in IPC [39].  181 
Table I shows the timeline of key national policies reports and campaigns for addressing MRSA. 182 
 183 
(iii) Comparing approaces in Japan and England 184 
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Organisational structures 185 
At the organisational level, in the five Japanese hospitals reviewed here, Infection Control 186 
Committees or Departments are positioned directly under the Hospital Director. In England, this 187 
varies and includes examples of large teaching university hospitals where the IPC Committee sits 188 
under the Clinical Effectiveness Committee, which in turns sits under the Hospital Board. In England, 189 
the Directors of Infection Prevention & Control (DIPCs) can be members of the Hospital Board, 190 
depending on their other organisational role. For example, if the DIPC is also Director of Nursing or 191 
Medical Director, they are part of the Board. In Japan, nurse leadership in infection control is yet to 192 
be seen. 193 
England has developed multidisciplinary IPC teams, extending beyond health professionals, including 194 
data managers/analysts and more recently surgical site infection (SSI) surveillance nurses and in 195 
some cases decontamination leads, in alignment with the 2015 Code of Practice in IPC [39]. In Japan, 196 
infection control also comprises multidisciplinary teams of health professionals, supported by admin 197 
staff but unlike England do not also include dedicated data management support.  198 
 199 
The role of media 200 
Newspapers in Japan have often reported nosocomial infection cases which have resulted in deaths 201 
but with little emphasis on AMR. Since 2016, however, AMR has become a worldwide problem and 202 
has been taken up as an agenda at the G7 Summit, with national newspapers covering the topic. The 203 
print and e-media has been publishing articles on the proper use of antibiotics and carrying out 204 
awareness-raising activities for citizens [101]–[105].  205 
 206 
Comparison of interventions within and between countries  207 
The total number of interventions in the period 2000-17 was 322 in England, compared to 119 in 208 
Japan. In England, there were two major peaks in the number of interventions around the periods of 209 
2007/08 – 2008/09 and 2012/13 - 2013/14. The second peak was linked to a refocus on MRSA 210 
through intense regulatory action combined with a series of persuasive, restrictive, and structural in 211 
nature interventions. These included zero tolerance, mandatory post infection review for all MRSA 212 
BSIs, financial penalties for hospitals breaching infection control standards, quality premiums (pay 213 
for performance framework), together with a national strategy (the UK Five Year AMR Strategy 2013-214 
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2018). In Japan, we see two large waves of sets of interventions introduced in 2007 and 2016 215 
respectively. The magnitude of peaks in England is about two-fold greater than in Japan (Figure 3). 216 
In England, there has been consistent focus on mandatory interventions, even after MRSA BSI rates 217 
dropped significantly. In Japan, interventions were primarily recommendations with successive 218 
increases observed 2013 onwards. Intensive focus on mandatory interventions in Japan was seen in 219 
2007 and 2014 (Figure 4). 220 
In both countries, campaigns started around the same time, but in England this type of intervention 221 
peaked in the years 2007/8 -2008/9, while in Japan campaigns were concentrated in the years 2003-222 
2004 and then ten years later. 223 
The target of campaigns in England has been wide, including health professionals, cleaning staff, 224 
patients and the public. In Japan, national campaigns have been less prevalent, while the target 225 
audience has often been narrower compared to England. For example, the Central Hospital Infection 226 
Control Council launched a campaign in 2003 targeting medical professionals and municipalities, 227 
excluding patients. Since publication of the AMR National Action Plan, however, campaigns have 228 
broadened. This includes an informative website and educational activities for citizens using user 229 
friendly SNS in response to calls from public institutions and non-profit organisations. The Japanese 230 
government added new modules of drug-resistant bacteria and proper use of antimicrobials in the 231 
curricula of medical schools in 2017. Furthermore, clinical seminars for doctors and dentists have 232 
been held across the country. The government also established the National International Medical 233 
Research Centre Hospital AMR Clinical Reference Centre (AMRCRC) in 2017.  234 
In England, interventions have been primarily structural, though in more recent years the picture has 235 
become more balanced with increasing emphasis also on persuasive and restrictive interventions. 236 
Japan has tended toward proportionally more persuasive interventions, with focused efforts on 237 
structural interventions in 2007 and 2014 (Figure 5). 238 
England has implemented more interventions targeted at the national (macro) level than Japan. 239 
England has also consistently, though to a lesser extent, also included micro-level focused 240 
interventions, whereas Japan has focused primarily at interventions implemented at the 241 
organisational (meso) level (Figure 6). 242 
(iv) Wider contextual analysis 243 
Distinctive features in each country are identified in the wider contextual policy domain which may 244 
have impacted on the nature and scope of MRSA-related interventions and their implementation. 245 
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The speed of success in the reduction of MRSA infections may be explained by these factors and 246 
approaches but causation of course cannot be attributed (Table II).  247 
 248 
Discussion 249 
In England there has been a substantial decrease in hospital MRSA BSIs in the last two decades, 250 
though there is still no consensus in the literature about which types of interventions were primarily 251 
responsible for bringing about this improvement; particularly as any such evaluation must also 252 
consider effects on other organisms [3], [6], [116]. In Japan, despite multiple interventions 253 
introduced and a notable decrease observed during the studied period, the prevalence of MRSA 254 
infections in hospitals remains relatively high. It is helpful to take a longitudinal and contextually 255 
grounded approach to such high-level comparative analysis. When comparing the availability and 256 
feedback of data at the organisational level, there is a gap in the Japanese context with limited data 257 
visualisation for the participating hospitals in the voluntary JANIS programme. It is difficult however 258 
to predict the impact of a voluntary versus mandatory scheme of reporting. A preference for 259 
national-level, mandatory and structural interventions in England reflects strong government 260 
intervention and a mainly top-down approach. The public character of the NHS and its integrated 261 
nature allowed for such an approach and resulted in a more uniform outcome at system-level. In 262 
contrast, the Japanese health system being more decentralised and characterised by stronger 263 
presence of the private sector emphasised recommendations and persuasive interventions targeting 264 
hospitals. For example, the development of guidelines in Japan has been largely driven by academic 265 
and professional societies, though lacking the next step of reinforcement and implementation via 266 
government action (as is the case in England). The top-down enforced target setting and monitoring 267 
approach in England has had very mixed responses from the professionals working within hospitals 268 
[117].  269 
Culturally, in Japan, the learning from the quality improvement movement in health and other 270 
sectors advocates internal (to the organisation) drivers and motivators [118]. This is seen also in the 271 
way that financial incentives (rather than punitive measures) for AMR interventions in Japan have 272 
been used (e.g. medical reimbursement system). In contrast in England, enforced policies mandate 273 
that the Chief Executive of the NHS Board is responsible for ensuring successful prevention and 274 
control of hospital infections; all NHS trusts need to appoint a DIPC, while Chief Executives are held 275 
personally responsible for the accuracy of infection data submitted by their trusts.  276 
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External international drivers seem to have influenced national activities particularly in Japan, 277 
whereas England, particularly with key opinion leaders such as Chief Medical Officers, have tended 278 
to take a leading role in a global scene influencing the development of Global Action Plan on AMR 279 
and World Alliance for Patient Safety (i.e. worldwide hand hygiene and surgical checklist campaigns).  280 
Alignment with WHO and other global interventions, such as the G7 Ise-Shima Summit 2016 and 281 
Japan’s National Action Plan on AMR seem to have led to increased national commitment by Prime 282 
Minister, media attention, and citizen-targeted education. 283 
It may be that an incremental approach to policy making [119] during short-term and unstable 284 
governments, and strong influence of vested groups helps to explain Japan as a late adopter of 285 
National Action Plans and other key policy interventions. In England, wider political windows of 286 
opportunity, political leaning of national governments, and the government’s determination to 287 
combat MRSA appear to be reflected in the two peaks of interventions. For example, strong focus on 288 
campaigns combined with NHS trust chief executives legal responsibility in MRSA (and CDI) reporting, 289 
and more on mandatory requirements during 2007/8-2008/9 and 2012/13-2013/14 respectively.  290 
In view of an increasing use of broad spectrum antimicrobials in Japan, some scholars suggest a 291 
restrictive approach to the use of fluoroquinolones [120]. Possible longer-term impacts of restrictive 292 
policy intervention on the reduction of MRSA through banning routine use of antibiotics has also 293 
been discussed in the UK context [121]. A way forward for Japan may be to further nurture intrinsic 294 
motivations and drivers with stable, supportive government combined with personal and 295 
professional stewardship [122] and regional governance [123], given the complex involvement of 296 
vested interest groups in policy making processes [124]. Addiitonally, if Japan were to shift from 297 
confidential to public reporting of MRSA, its unintended consequences should be monitored [125].  298 
The methods of healthcare funding and reimbursement mechanisms can influence antibiotic 299 
prescription [126], hence consequently affecting AMR. In Japan, it is possible to induce the 300 
implementation of healthcare by revising medical fees every two years. However, such system would 301 
require commitment from hospital leads.  302 
 A higher level of healthcare utilisation and unique demographic shifts with falling birth rates to 303 
contribute to healthcare funding for increasing aging population in Japan are also a reminder of 304 
challenges which lay ahead. Addressing avoidable costs to healthcare are therefore a priority.  305 
From a more sociological perspective, the relationship between national cultural values and 306 
behaviour change in relation to IPC and antimicrobial stewardship needs to be investigated in Japan 307 
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where there are relatively higher power distance and uncertainty avoidance scores and slow 308 
progress in the reduction of MRSA [127]–[129].  309 
Strengths and Limitations of the study.  310 
We looked at the trends and patterns of MRSA and the relevant interventions since 2000 in an 311 
attempt to build and compare epidemiological settings across Japan and the UK, however direct 312 
comparisons in numbers could not be made due to different reporting units used. We recognise the 313 
difficulty of assessing the genuine effect of one specific intervention due to the concurrent existence 314 
of interventions that are often multimodal.  There are also limitations in capturing the degree, 315 
duration and timing of implementation of interventions. Policy change and availability of new 316 
diagnostic technologies are factors which may affect the volume of clinical specimens. These factors 317 
are relevant for both Japan and England. There has been a high intensity of interventions in England 318 
for antimicrobial stewardship and IPC compared to Japan.  The very nature of surveillance comes 319 
with limitations, and systems where a review process to verify infections and why they have 320 
happened provides information for learning.  Future research will address local level implementation 321 
and perceptions of the interventions presented here through primary data (e.g. interviews with key 322 
informants) to triangulate and/or understand local effects. Future work must also understand the 323 
profile and trends in the community and across the whole health economy. 324 
As an initial analysis, Leichter’s four main dimensions of contextual factors are helpful for 325 
understanding potential for transferability between countries, but a more detailed analysis of 326 
governance approaches would be beneficial [3]. The approach here neglects the reality of complex 327 
and dynamic social phenomena but provides a framework for future cross-national comparisions for 328 
mutual learning. 329 
 330 
Conclusions  331 
In Japan, international drivers seem to have led to increased national commitment, but nationally, 332 
the approach is characterised by voluntary surveillance and a more persuasive approach for clinical 333 
professionals rather than a mandatory approach for institutional management. England has reached 334 
the extremes of mandatory reporting and ever increasing information in the public domain. 335 
Interventions need to be temporally relevant to the epidemiological trend, but also acceptable 336 
within the health system, culture and public expectations. Lessons from other high-income countries 337 
can help inform the right mix of interventions to create sustainable and resilient systems for future 338 
infection and economic challenges.  339 
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Table I 
Comparison of the overview of key policies, guidelines, reports, and campaigns for MRSA and other 
relevant interventions between Japan and England. 
Japan Year England 
Introduction of nation-wide voluntary surveillance 
(JANIS) – MHLW [14]. 
2000 DH issued Health Service Circular 2000/002: The management and 
control of hospital infection: action for the NHS for the management 
and control of infection in Hospitals in England [40].  
Revision of medical reimbursement system: Hospital 
without ICT would subtracted fees (0.5 US$ or £0.4) – 
MHLW [41]. 
 DH issued UK antimicrobial resistance strategy and action plan [42].  
 
First Infection Control Doctors were certified. [43]  DH issued, The NHS Plan - A plan for investment, a plan for reform. Star 
ratings to be introduced. National cleaning standards to be monitored 
by Patient Environment Action Teams (PEAT). ‘Modern matrons’ to have 
the authority at ward level to ensure hospital cleanliness and right care 
for patients. A trust board member to be nominated to assume 
responsibility to monitor hospital cleanliness and report regularly to the 
board. [44]  
18 Nurses certified as first Infection Control Nurses [33]. 2001 Introduction of mandatory surveillance for MRSA BSIs [45].  
Inauguration of the MHLW.  NHS Estates issued National Standards of Cleanliness for the NHS for the 
first time [46].  
Held an expert opinion meeting on hospital infection 
control [47]. 
2002 The first results for MRSA mandatory surveillance data (April 2001 - 
September 2001) published in February 2002.  
  Infection control in the built environment: design and planning, 
published by NHS Estates. Emphasised the importance of involvement 
of health staff and infection control teams in designing and planning of 
health facilities.[48]  
‘Future measures for nosocomial infection control’ was 
released by expert opinion meeting on hospital infection 
control - Construction of a grand design for nationwide 
nosocomial infection control. The organisation the tasks 
from each stakeholder [47]. 
2003 DH issued Winning ways: working together to reduce healthcare 
associated infection in England, a report from the Chief Medical Officer 
[49].  
 
Revised Act on the Prevention of Infectious Diseases and 
Medical Care for Patients with Infectious Diseases was 
released [50].  
  
 
‘Central Conference on Infection Control in Hospital’ was 
established as a permanent advisory body by MHLW 
[51]. 
2004 Mandatory surveillance of orthopaedic surgical site infections began in 
trusts.  
  DH issued Towards cleaner hospitals and lower rates of infection: a 
summary of action [52]. Patients were concerned about poor hospital 
cleanliness and increasing MRSA infections.  
  National standards, local action: Health and Social Care Standards and 
Planning Framework 2005/2006–2007/2008 [53].  
  National Patient Safety Agency launched cleanyourhands campaign to 
implement near patient alcohol hand rubs [54]. First in the world.  
  National target reduction for the number of incidents of MRSA BSIs by 
50% over 3 year period (April 2005 – March 2008) compared to the 
2003/04 baseline data [55]. Mandatory target introduced to hospitals in 
November 2004. 
  All NHS trusts to appoint a DIPC, who has authority and responsibility 
for the reduction of HCAIs (e.g., directly reporting to the trust chief 
executive and trust board, writing and publishing an annual report on 
HCAIs).[49]  
Revision of ‘Regulation for Enforcement of Medical Care 
Act’ – MHLW [56]. 
2005 DH issued Saving Lives: a delivery programme to reduce healthcare 
associated infection including MRSA [57]. The first version of Saving 
Lives programme. Saving Lives campaign, including High Impact 
Interventions based on the ‘care bundle’ principle.  
‘Prevention of in-hospital infection in medical facilities’ 
was released by MHLW [58]. Points which regard 
nosocomial infection prevention based on the latest 
scientific evidence.  
 Introduction of Mandatory MRSA bacteraemia enhanced surveillance 
scheme [59]. Health protection Agency developed and introduced an 
enhanced MRSA reporting system, moving from aggregated acute trust 
level to patient-level data collection using web-based Data Capture 
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Japan Year England 
System with ‘real-time’ nature, and that enabled to identify the 
presence of the BSI on admission.  
Mandatory assignment of dedicated infection control 
personnel at Advanced Treatment Hospitals [47], [56], 
[60]. 
  
Revision of medical reimbursement system: Hospital 
with medical safety measures could receive additional 
fees (4.7 US$ or £3.3)[61]. 
2006 The Chief Medical Officer made chief executive of the NHS trust board 
personally responsible for the accuracy of infection data submitted by 
their trusts [62].  
  DH issued Going further faster: implementing the Saving Lives delivery 
programme - Sustainable change for cleaner, safer care. Set out actions 
aimed to reduce MRSA, and in turn, support system-wide improvement 
in HCAIs (e.g. ensuring infection control (induction & ongoing) training 
for hospital staff, inclusion of infection control in job description).[63] 
  Health Act 2006 (c.28), requirement for provider registration with 
regulator, legal requirement for providers to ensure protection against 
HCAIs [64].  
  Health Act 2006: Code of Practice for the prevention and control of 
healthcare associated infections issued [65]. Known as The ‘Hygiene 
Code’, applied to all NHS healthcare providers. Improvement Notice 
from the regulatory body for failing to observe the Code, or special 
measures for significant failings.  
  DH’s Healthcare Associated Infection Improvement Team established, 
and paid visits to acute hospitals to help trusts reduce MRSA BSIs. 
Doubled the size of the expert Improvement Team by October 2007 
when Lord Darzi’s interim report released. [66] 
Partial revision of Infectious Disease Act – Tuberculosis 
prevention law was integrated into this act [67]. 
2007 DH published Uniforms and workwear: an evidence base for developing 
local policy [68]. Known as the ‘bare below the elbows’ guidance.  
Partial revision law for the revision of Medical Care Act 
enacted- This law was obligatory for all medical 
institutions to establish measures to prevent in-hospital 
infection [69]. 
 The Secretary of State for Health announced a series of measures to 
combat HCAIs, including a legal requirement for NHS trusts chief 
executives to report MRSA BSIs (and CDI) to Health Protection Agency 
with fines for non-compliance; cleanyourhands campaign to be 
continued.  
‘Guide and training program of medical safety manger’ 
was settled by MHLW – This document summarised the 
education programmes for medical safety mangers. It 
clarified the work for a medical safety manger [70]. 
 DH issued Isolating patients with healthcare-associated infection: a 
summary of best practice [71]. 
‘Measures to prevent in-hospital infection by drug-
resistant bacteria and responses after occurrence’- 
MHLW – This document requests hospitals to change 
criteria of suspected an outbreak [72]. 
 Improving cleanliness and infection control (Professional letter from 
Chief Nursing Officer/Director General of Finance). 5 key action areas in 
nursing (e.g. increasing the number of matrons to 5000 in acute NHS 
hospitals by May 2008, quarterly mandatory reporting on cleanliness 
and infection control by matrons and clinical directors to trust boards, 
etc.). [73]  
JANIS Open Reports are available via internet since 2007 
[14]. 
 Deep clean campaign. The Secretary of State for Health announced 
Deep Clean initiative ‘as part of the drive for a culture of cleanliness’, an 
initial deep cleaning to have conducted by all NHS trusts before 31 
March 2008. [66]  
  DH issued The NHS in England: Operating Framework for NHS, 
2008/2009 - locally agreed stretch targets alongside national targets for 
improving cleanliness and reducing MRSA & C. difficile were announced 
[74].  
Japanese Society for Infection Prevention and Control 
started the Device-related infection surveillance [75].  
2008 DH issued Clean, safe care: reducing infections and saving lives [76]. 
Promotion of innovations / new technologies and equipment was 
emphasised.  
Board Certified Pharmacist in Infection Control, by the 
Japanese Society of Hospital Pharmacists. 
 Health and Social Care Act 2008 (c.14), required registration with the 
Care Quality Commission, and duty to protect patients against HCAIs 
[77]. New code of practice.  
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Japan Year England 
  MRSA screening operational guidance 2. Supplementary guidance to 
support trusts in introducing MRSA screening for all elective patients in 
March 2009.[78] 
 2009 MRSA objective 2010/11 – relative to the median, with the best 
performers setting their objectives locally; embedding a culture of zero 
tolerance of preventable infections across any organisation (DH)[79].  
Revision of medical reimbursement system: Hospital 
with ICT could receive additional fees (12 US$ or £8.5) – 
MHLW [80]. 
2010 MRSA screening operational guidance 3 [81]. Supported NHS 
organisations in introducing MRSA screening for all relevant emergency 
admissions in December 2010.  
MHLW issued the notification - About the establishment 
of ICT, the frequency and structure of ICT ward round, 
standards about outbreak [82]. 
2011 ‘Start Smart - Then Focus’ launched - Guidance on antimicrobial 
stewardship in the secondary healthcare setting [83].  
 
Revision of medical reimbursement system: Hospital 
with advanced infection control management could 
receive additional fees (12 to 48 US$ or £8.5 - 34) – 
MHLW [84].     
2012 Everyone counts: planning for patients 2013/14 [37]. Zero tolerance 
approach to MRSA bloodstream infections and mandatory Post Infection 
Review. Introduced on 1st April 2013.  
Guideline for treatment of MRSA infection was 
published by the Japanese Association for Infectious 
Diseases/Japanese Society of Chemotherapy [85]. 
2013 The Chief Medical Officer’s annual report on Infections and the rise of 
antimicrobial resistance [86].  
  Locally set objectives for incidence of MRSA (& C. difficile) infection 
included in Quality Premium for CCGs, 12.5% (subject to the following 
achievements: no cases of MRSA bacteraemia assigned to the CCG). (In 
2014/15, this was removed from Quality Premium). [87]   
  DH issued UK Five year antimicrobial resistance strategy 2013 -2018 [4].  
  Everyone counts: planning for patients 2014/15-2018/19 [88] - 
reiterates zero tolerance to MRSA (NHS England).  
  NHS Standard Contract 2014/15 Particulars [89] issued in December 
2013- National Quality Requirements for 2014/15 financial year – zero 
tolerance MRSA a national quality requirement (threshold 2014/15 is 
˃0). Consequence of breach £10 000 in respect of each MRSA incidence 
in the relevant month (NHS England).  
MHLW issued new definition of outbreak [47], [90].  
 
2014 DH published Implementation of modified admission MRSA screening 
guidance for NHS [91]. Recommended ‘a more focused, cost-effective 
approach to MRSA screening’.  
  English Surveillance Programme for Antimicrobial Utilization and 
Resistance (ESPAUR), established by Public Health England. 1
st
 repot 
published in September 2014 [92].  
  Antibiotic Guardian Campaign, launched in association with European 
Antibiotic Awareness Day. Developed by various organisations, including 
Public Health England, and promotes everyone to pledge appropriate 
use of antibiotics.[93], [94]  
MHLW issued recommendations on drug-resistant 
bacterial policy [95].  
2015 National Risk Register of Civil Emergencies, 2015 edition, by Cabinet 
Office [96]. AMR was placed on the UK government risk register.  
  Antibiotic Quality Premium (NHS England), aiming to improve antibiotic 
prescribing in primary and secondary care. CCGs rewarded for quality 
improvement, paid in the following financial year, and must be 
reinvested in quality or health outcome improvement.[97]  
  DH issued The Health and Social Care Act 2008: Code of Practice on the 
prevention and control of infections and related guidance [39].  
MHLW issued AMR National Action Plan [5]. 2016 CQUIN Guidance for 2016/17, issued by NHS England [98]. AMR became 
one of 4 national indicators for CQUIN. 
  AMR local indicators profile (including local surveillance data) on the 
‘Fingertips’ data portal (publicly accessible interactive web tool and 
enhanced data visualisation), launched by Public Health England [99]. 
Guideline for treatment of MRSA infection, 2
nd
 edition 
was revised by The Japanese Association for Infectious 
Diseases/Japanese Society of Chemotherapy [100]. 
2017  
Abbreviations: AMR, antimicrobial resistance; BSIs, bloodstream infections; CCGs, Clinical Commissioning Groups; C. 
difficile, Clostridium difficile; CDI, Clostridium difficile infection; CQUIN, Commissioning for Quality and Innovation; DH, 
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Department of Health; DIPC, Director of Infection Prevention and Control; HCAIs, healthcare-associated infections; ICT, 
infection control team; JANIS, Japan Nosocomial Infections Surveillance; MHLW, Ministry of Health, Labour and Welfare; 
MRSA, methicillin-resistant Staphylococcus aureus; NHS, National Health Service; UK, United Kingdom. 
NB: CCGs are responsible for commissioning care for defined geographical populations (2013-).
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Table II  
Comparison of the wider contextual factors and approaches to MRSA reduction / quality improvement between Japan and England (/UK) 
Factor Component  Japan England (/UK) 
SITUATIONAL POLITICAL 
Change of government 
& national leadership 
Political leadership instability: 
• 15 terms of office (7 general election since 2000) of an average length of 1.9 years 
between July 1998 – December 2017 (range 0.8 -5.4 years). 
• September 2006 - December 2012: frequent leadership changes with 6 different prime 
ministers occurred, but only one prime minister since December 2012. 
• 10 coalition governments – primarily led by Liberal Democratic Party (LDP, Jiminto - 
Conservative), and shifted to Democratic Party of Japan (DPJ, Minshuto - Centrist), and 
then back to LDP. 
•The minister of Health, Labour and Welfare also changes frequently according to the 
governments. The current one was appointed at August 2017. 
Wider political windows of opportunity for policy change: 
• 8 terms of office of an average length of 4.1 years between May 1997 – December 
2017 (range 1.2- 10.1 years).  
• 5 governments have been majority with 1 as coalition, shifting from Labour (Centre 
Left) with 2 different prime ministers to Conservative-Liberal Democratic, and to 
Conservative with 2 different prime ministers. 
• Secretary of State for Health was more stable under Coalition and Conservative 
governments rather than Labour governments (Centre Left & Left) in earlier periods, 
accounting for 1 and 4 turnovers respectively. The current one serving over 6 years 
(name changed to Secretary of State for Health and Social Care in January 2018). 
HEALTH 
Life expectancy at birth 
(years)[106] 
81 (2000) → 84 (2016) 
 
78 (2000) → 81 (2016)   [UK] 
Top five causes of death 
(age-standardised rate 
per 100 000 population 
by cause) between 2000 
and 2016 [107] 
1) Stroke 50.5 (2000);  
2) Ischaemic heart disease 43.8 (2000); 
3) Lower respiratory infections 32.7 (2000); 
4) Trachea, bronchus, lung cancer 21.9 (2000); 
5) Stomach cancer 21.6 (2000) 
 
1) Ischaemic heart disease 31.5 (2016); 
2) Stroke 25.8 (2016); 
3) Lower respiratory infections 24.3 (2016); 
4) Trachea, bronchus, lung cancer 19.6 (2016) 
5) Self-harm 14.3 (2016) 
1) Ischaemic heart disease 114.7 (2000); 
2) Stroke 47.3 (2000); 
3) Lower respiratory infections 46.0 (2000); 
4) Trachea, bronchus, lung cancer 32.7 (2000) 
5) Chronic obstructive pulmonary disease 26.9 (2000) 
 
1) Ischaemic heart disease 47.6 (2016); 
2) Alzheimer disease and other dementias 37.6 (2016); 
3) Trachea, bronchus, lung cancer 26.7 (2016); 
4) Chronic obstructive pulmonary disease 23.1 (2016) 
5) Stroke 21.6 (2016)    [UK] 
HEALTH CARE UTILISATION 
Doctors consultations 
(in all settings) – 
Number per capita [108]  
14.4 (2000) →12.7 (2014) 
 
 
5 (2009)   [UK] 
Occupancy rate of 
curative (acute) care 
beds [109] 
81.8% (2000) → 74.5% (2015) 
 
 
83.4% (2001) → 84.3% (2010)   [UK] 
Average length of stay 
in hospital (days)[109] 
24.8 (2000) → 16.5 (2015) 10.7 (2000) → 7.0 (2015)   [UK] 
STRUCTURAL  POPULATION 
Population structure by 
age group (% of total) 
[106]  
Aged 0-14: 15% (2000) → 14% (2008) → 13% (2016) 
Aged 15-64: 68% (2000) → 65% (2008) → 60% (2016) 
Aged 65 and above: 17% (2000) → 21% (2008) → 27% (2016) 
NB - Japan population, thousands: 127,534 (2000) → 127,749 (2016) [107]. 
Aged 0-14: 19% (2000) → 18% (2008) → 18% (2016) 
Aged 15-64: 65% (2000) → 66% (2008) → 64% (2016) 
Aged 65 and above: 16% (2000) → 16% (2008) → 18% (2016) 
NB - UK population, thousands: 58,951 (2000) → 65,789 (2016) [107]. 
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Factor Component  Japan England (/UK) 
Density of population 
(people per sq. km of 
land area) [106] 
348 (2000) → 348 (2016) 
 
 
243 (2000) → 271 (2016)   [UK] 
SOCIO-ECONOMIC 
GDP per capita (current 
US$, thousands)[106] 
38.53 (2000) → 40.86 (2009) → 38.97 (2016) 
 
27.98 (2000) → 38.26 (2009) → 40.41 (2016)  [UK] 
Unemployment, total 
(% of total labour 
force)(modelled ILO 
estimate)[106] 
4.7 (2000) → 5.1 (2009) → 2.8 (2017) 
 
 
 
5.6 (2000) → 7.5 (2009) → 4.3 (2017)   [UK] 
 
Poverty rate (% below 
poverty line of 60%) 
[110]  
22%  18%   [UK] 
 
HEALTHCARE MODELS 
Healthcare models [111] Bismarck Model. 
Statutory health insurance system with a mixture of state regulation, social insurance 
financing, and private care provision [112]. 
The medical payment is calculated based on medical fee points. Patients pay part of this 
amount, and the public health insurance pays the remainder. The revision of the medical 
fee points is decided by the cabinet, the committee on health insurance, and the central 
social insurance medical council.  These medical fee points are revised every two years. 
Beveridge Model. 
NHS being publicly funded through taxation, and characterised by state regulation and 
control in the provision of services [112]. 
Public system financing 
[113]  
General tax revenue; insurance contributions. 
 
General tax revenue (includes employment-related insurance contributions). [England] 
Provider ownership – 
hospitals [113] 
Mainly private non-profit (~70% of beds), some public (~30%). Mostly public, some private. [England] 
Hospital payment [113] Case-based per diem payments and fee-for-service or fee-for-service only (includes 
physician costs). 
Mainly case-based payments (60%) plus budgets for mental health, education, and 
research and training. All include physician costs, drug costs, etc. [England] 
HEALTH EXPENDITURE 
Total expenditure on 
health (% of GDP) 
(2016) [109] 
Total: 10.9 
 
Total: 9.7   [UK] 
 
Health expenditure by 
type of financing (2015) 
[109] 
Government schemes: 9% 
Compulsory health insurance: 75% 
Out-of-pocket: 13% 
Voluntary health insurance: 2% 
Other: 1% 
Government schemes: 80% 
Compulsory health insurance: 0% 
Out-of-pocket: 15% 
Voluntary health insurance: 3% 
Other: 2%     [UK] 
Health expenditure by 
provider (2015)[109] 
Hospitals: 41% 
Long-term care facilities:9% 
Ambulatory providers: 28% 
Retailers: 17% 
Other:  5% 
Hospitals: 42% 
Long-term care facilities: 12% 
Ambulatory providers: 23% 
Retailers: 11% 
Other: 12%     [UK] 
HEALTH WORKFORCE  
Practising doctors per 
1000 pop.[109] 
1.9 (2000) → 2.4 (2014) 
 
2.0 (2000) → 2.8 (2015)   [UK] 
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Factor Component  Japan England (/UK) 
Practising nurses per 
1000 pop.[109]  
8.4 (2002) → 11.0 (2014)  7.9 (2015)   [UK] 
Ratio of nurses to 
doctors [109] 
4.6 (2015) 
 
2.8 (2015)   [UK] 
Practising pharmacist 
per 100 000 pop. [109] 
113 (2000) → 170 (2015) 59 (2002) → 83 (2015)   [UK] 
HEALTH INFRASTRUCTUTRE 
Hospital beds per 1000 
pop. [109]  
14.7 (2000) → 13.2 (2015)  4.1 (2000) → 2.6 (2015)   [UK] 
Cultural  *National culture score 
(Hofstede country 
scores based on 6 
dimensions)[114] 
1) Power distance: 54 
2) Individualism: 46 
3) Masculinity: 95 
4) Uncertainty avoidance: 92 
5) Long-term orientation: 88 
6) Indulgence: 42  
1) Power distance: 35 
2) Individualism: 89 
3) Masculinity: 66 
4) Uncertainty avoidance: 35 
5) Long-term orientation: 51 
6) Indulgence: 69     [UK]  
Exogenous Influence of 
international 
institutions 
International alignment and influences apparent, especially US influence. e.g. 12% of 
interventions identified 2000-17, including MRSA related guidelines based on the Centers 
for Disease Control (CDC) guidelines and literature reviews, and regularly updated. 
Nationally-based initiatives ahead of aspects of global initiatives. 
 
 
Approaches to  
MRSA reduction / 
quality 
improvement  
Requirement of 
surveillance  
Voluntary: 
JANIS voluntary surveillance scheme since 2000 (but more comprehensively since 2007).  
Mandatory: 
National MRSA mandatory surveillance since 2001. Zero tolerance approach to MRSA 
bloodstream infections and mandatory Post Infection Review (replacing previous root 
cause analysis) since April 2013. 
Mode of reporting / 
accountability 
Closed information – confidential reporting: 
Hospital names are anonymised in JANIS open data sources, not intending to promote 
competitions between hospitals, but to encourage them to improve against their own 
historical performance trajectories (as bench-marking). 
Open information – public reporting: 
Detailed information disclosure to the public done in an early period (e.g. public 
reporting of MRSA bloodstream infections at trust level began in 2002). 
Mode of motivation Mainly intrinsic but with long-term objectives based largely on principles of Kaizen 
(continuous quality improvement).   
Both extrinsic & intrinsic. 
 
Examples of incentive / 
sanction 
Financial incentive: Many AMR interventions use financial incentives such as medical 
reimbursement system. 
 
Process-oriented sanction: Monetary sanctions were held at one time, and the sanctions 
targeted the infection control measure at hospitals. Process indicators considered as 
useful in Japan because immediate changes can be implemented.  
Financial incentive: Commissioning for Quality and Innovation (CQUIN); quality premium. 
 
Outcomes-oriented sanction: Monetary sanctions were held for hospitals that cannot 
fulfil target reduction rates. 
Abbreviations: AMR, antimicrobial resistance; GDP, Growth Domestic Product; JANIS, Japan Nosocomial Infections Surveillance; MRSA, methicillin-resistant Staphylococcus aureus; NHS, National Health Service.   
NB: The UK comprises England, Scotland, Wales, and Northern Ireland. The data that are only available for the UK are specified in the table.  
*1) Power distance: the degree to which the less powerful members of a society accept and expect that power is distributed unequally; 2) Individualism (versus Collectivism): preference for a loosely-knit social 
framework in which individuals are expected to take care of only themselves and their immediate families; 3) Masculinity (versus Femininity): a preference in society for achievement, heroism, assertiveness, and 
material rewards for success; 4) Uncertainty avoidance: the degree to which the members of a society feel uncomfortable with uncertainty and ambiguity; 5) Long-term orientation (versus short-term normative 
orientation): Long-term orientation takes a more pragmatic approach, encouraging thrift and efforts in modern education as a way to prepare for the future; 6) Indulgence (versus Restraint): Indulgence stands for a 
society that allows relatively free gratification of basic and natural human drives related to enjoying life and having fun. [115] 
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Figure 1. Trends in rates of seven (multi)drug-resistant bacterial infections in Japan based on Antimicrobial-Resistant Bacterial Infection (ARBI) data 
(Average hospital participation rates ranged between 3% and 10% in 2007 and 2016 respectively); the 2007 data represent the average of July-December 
2017 data) [15].   
Abbreviations: MDRP, Multidrug-resistant Pseudomonas aeruginosa; PRSP, Penicillin-resistant Streptococcus pneumoniae.  Note: Value of vancomycin-resistant Staphylococcus aureus (VRSA) 
indicates nil during the above period.
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Figure 2. Trends in rates of MRSA, MSSA and E. coli bloodstream infections, and C. difficile infection 
(patients aged 2 years and over) for NHS acute trusts – All reported cases (England average)[8]–[12]   
Abbreviations: MRSA, meticillin-resistant Staphylococcus aureus; BSI, blood stream infection; MSSA, meticillin-sensitive S. 
aureus; CDI, Clostridium difficile infection.  
NB: 1) April 2001: Mandatory surveillance for MRSA BSIs; 2) January 2004: Mandatory surveillance of C. difficile-associated 
diarrhoea (CDAD) in patients aged 65 years and over began in NHS trusts; 3) April 2007: Mandatory surveillance of CDIs 
extended to all cases in patients aged 2 years and over for acute NHS trusts; 4) January 2011: Mandatory surveillance 
extended to meticillin-sensitive S. aureus BSIs; 5) June 2011: Mandatory surveillance extended to Escherichia coli BSIs. 
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Figure 3. Trends in MRSA and total number of relevant interventions: Japan (left) and England (right) 
Abbreviations: MRSA, meticillin-resistant Staphylococcus aureus; BSI, bloodstream infection. Note: The 2007 MRSA infection data represent the average of July-December 2017 data. 
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Figure 4. Trends in MRSA and intervention type: Japan (left) and England (right) 
Abbreviations: MRSA, meticillin-resistant Staphylococcus aureus; BSI, bloodstream infection. Note: The 2007 MRSA infection data represent the average of July-December 2017 data. 
a: [campaign] Report of the Central Conference on Nosocomial Infection Control (September 2003). 
b: [recommendation(g)] Infection control manual in elderly care welfare facility. Ministry of Health, Labour and Welfare, Japan (March 2013). 
c: [mandatory] Infectious Disease Act (Prevention of Infectious Diseases and Medical Care for Patients with Infectious Diseases), revised. Ministry of Health, 
Labour and Welfare, Japan (November 2016). 
d: [campaign] Cleanyourhands for hand hygiene improvement began, England and Wales (September 2004). 
e: [mandatory] The Health Act 2006 (c.28) introduced requirement for provider registration with regulator, requirement for providers to ensure protection 
against HCAI, and (new) Code of Practice for the prevention and control of HCAIs (July 2006). 
f: [recommendation] National Institute for Health and Clinical Excellence (NICE) issued Surgical site infection: prevention and treatment of surgical site 
infection (CG74)(October 2008). 
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Figure 5. Trends in MRSA and the nature of relevant interventions: Japan (left) and England (right) 
Abbreviations: MRSA, meticillin-resistant Staphylococcus aureus; BSI, bloodstream infection. Note: The 2007 MRSA infection data represent the average of July-December 2017 data. 
g: [persuasive & structural] Japan Nosocomial Infections Surveillance (voluntary) began in 2000, but system change occurred in 2007 and consequently all 
surveillance data became available via internet (2007-). 
h: [restrictive & persuasive]  Implementing an Antibiotic Stewardship Programme, Guidelines by the American Society of Infectious Diseases and the 
American Medical Epidemiology Association (translated into Japanese)(May 2016). 
i: [persuasive] Infection Control Manual for Pharmacists, 4
th
 revision, Japanese Society of Hospital Pharmacists (April 2017).  
j: [structural & restrictive] Introduction of mandatory surveillance for MRSA BSIs (April 2001).  
k: [structural] Mandatory MRSA reporting changed from paper to a web-based system (January 2008). 
l: [persuasive] Royal College of Nursing issued Wipe it out - one chance to get it right: Infection prevention and control - Information and learning resources 
for health care staff (January 2014)  
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Figure 6. Trends in MRSA and level of implementation of relevant interventions: Japan (left) and England (right) 
Abbreviations: MRSA, meticillin-resistant Staphylococcus aureus; BSI, bloodstream infection.  Note: The 2007 MRSA infection data represent the average of July-December 2017 data. 
m: [macro, meso & micro] Infection Control Nursing Certified Nurse Specialist – Japanese Nursing Association. (Hospitals cannot obtain medical treatment 
compensation unless there is at least one nurse who has received appropriate education for infection control) (2006-). 
n: [macro & meso] Measures to prevent in-hospital infection by drug-resistant bacteria and response after occurrence. Ministry of Health, Labour and 
Welfare, Japan (October 2007). 
o: [meso] Guidelines for small and medium-sized hospitals and clinics and early identification of outbreaks. Ministry of Health, Labour and Welfare, Japan 
(2009). 
p: [meso] National evidence-based guidelines for preventing healthcare-associated infections in NHS hospitals in England (epic1) published
 
(January 2001). 
q: [macro & meso] Everyone counts: planning for patients 2013/14 (December 2012) - Zero tolerance approach to MRSA BSIs and mandatory Post Infection 
Review mentioned. Required all NHS organisations (that report positive cases) to conduct a Post Infection Review from 1 April 2013. 
r: [macro & micro] Health Education England issued, e-Learning e-LfH. Infection prevention and control modules: level 1 (2015). 
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LEGENDS: 
Figure 1. Trends in rates of seven (multi)drug-resistant bacterial infections in Japan based on Antimicrobial-Resistant Bacterial Infection (ARBI) data 
(Average hospital participation rates ranged between 3% and 10% in 2007 and 2016 respectively); the 2007 data represent the average of July-December 
2017 data) [15].   
Abbreviations: MDRP, Multidrug-resistant Pseudomonas aeruginosa; PRSP, Penicillin-resistant Streptococcus pneumoniae.  Note: Value of vancomycin-resistant Staphylococcus aureus (VRSA) 
indicates nil during the above period. 
 
  
 
Figure 2. Trends in rates of MRSA, MSSA and E. coli bloodstream infections, and C. difficile infection (patients aged 2 years and over) for NHS acute trusts – 
All reported cases (England average)[8]–[12]   
Abbreviations: MRSA, meticillin-resistant Staphylococcus aureus; BSI, blood stream infection; MSSA, meticillin-sensitive S. aureus; CDI, Clostridium difficile infection.  
NB: 1) April 2001: Mandatory surveillance for MRSA BSIs; 2) January 2004: Mandatory surveillance of C. difficile-associated diarrhoea (CDAD) in patients aged 65 years and over began in NHS 
trusts; 3) April 2007: Mandatory surveillance of CDIs extended to all cases in patients aged 2 years and over for acute NHS trusts; 4) January 2011: Mandatory surveillance extended to 
meticillin-sensitive S. aureus BSIs; 5) June 2011: Mandatory surveillance extended to Escherichia coli BSIs. 
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Figure 3. Trends in MRSA and total number of relevant interventions: Japan (left) and England (right) 
Abbreviations: MRSA, meticillin-resistant Staphylococcus aureus; BSI, bloodstream infection. Note: The 2007 MRSA infection data represent the average of July-December 2017 data. 
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Figure 4. Trends in MRSA and intervention type: Japan (left) and England (right) 
Abbreviations: MRSA, methicillin-resistant Staphylococcus aureus; BSI, bloodstream infection. Note: The 2007 MRSA infection data represent the average of July-December 2017 data. 
a: [campaign] Report of the Central Conference on Nosocomial Infection Control (September 2003). 
b: [recommendation(g)] Infection control manual in elderly care welfare facility. Ministry of Health, Labour and Welfare, Japan (March 2013). 
c: [mandatory] Infectious Disease Act (Prevention of Infectious Diseases and Medical Care for Patients with Infectious Diseases), revised. Ministry of Health, 
Labour and Welfare, Japan (November 2016). 
d: [campaign] Cleanyourhands for hand hygiene improvement began, England and Wales (September 2004). 
e: [mandatory] The Health Act 2006 (c.28) introduced requirement for provider registration with regulator, requirement for providers to ensure protection 
against HCAI, and (new) Code of Practice for the prevention and control of HCAIs (July 2006). 
f: [recommendation] National Institute for Health and Clinical Excellence (NICE) issued Surgical site infection: prevention and treatment of surgical site 
infection (CG74)(October 2008). 
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Figure 5. Trends in MRSA and nature of relevant interventions: Japan (left) and England (right) 
Abbreviations: MRSA, methicillin-resistant Staphylococcus aureus; BSI, bloodstream infection. Note: The 2007 MRSA infection data represent the average of July-December 2017 data. 
g: [persuasive & structural] Japan Nosocomial Infections Surveillance (voluntary) began in 2000, but system change occurred in 2007 and consequently all 
surveillance data became available via internet (2007-). 
h: [restrictive & persuasive]  Implementing an Antibiotic Stewardship Programme, Guidelines by the American Society of Infectious Diseases and the 
American Medical Epidemiology Association (translated into Japanese)(May 2016). 
i: [persuasive] Infection Control Manual for Pharmacists, 4
th
 revision, Japanese Society of Hospital Pharmacists (April 2017).  
j: [structural & restrictive] Introduction of mandatory surveillance for MRSA BSIs (April 2001).  
k: [structural] Mandatory MRSA reporting changed from paper to a web-based system (January 2008). 
l: [persuasive] Royal College of Nursing issued Wipe it out - one chance to get it right: Infection prevention and control - Information and learning resources 
for health care staff (January 2014)  
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Figure 6. Trends in MRSA and level of implementation of relevant interventions: Japan (left) and England (right) 
Abbreviations: MRSA, methicillin-resistant Staphylococcus aureus; BSI, bloodstream infection.  Note: The 2007 MRSA infection data represent the average of July-December 2017 data. 
m: [macro, meso & micro] Infection Control Nursing Certified Nurse Specialist – Japanese Nursing Association. (Hospitals cannot obtain medical treatment 
compensation unless there is at least one nurse who has received appropriate education for infection control) (2006-). 
n: [macro & meso] Measures to prevent in-hospital infection by drug-resistant bacteria and response after occurrence. Ministry of Health, Labour and 
Welfare, Japan (October 2007). 
o: [meso] Guidelines for small and medium-sized hospitals and clinics and early identification of outbreaks. Ministry of Health, Labour and Welfare, Japan 
(2009). 
p: [meso] National evidence-based guidelines for preventing healthcare-associated infections in NHS hospitals in England (epic1) published
 
(January 2001). 
q: [macro & meso] Everyone counts: planning for patients 2013/14 (December 2012) - Zero tolerance approach to MRSA BSIs and mandatory Post Infection 
Review mentioned. Required all NHS organisations (that report positive cases) to conduct a Post Infection Review from 1 April 2013. 
r: [macro & micro] Health Education England issued, e-Learning e-LfH. Infection prevention and control modules: level 1 (2015). 
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